RU2019113370A - Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения - Google Patents
Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения Download PDFInfo
- Publication number
- RU2019113370A RU2019113370A RU2019113370A RU2019113370A RU2019113370A RU 2019113370 A RU2019113370 A RU 2019113370A RU 2019113370 A RU2019113370 A RU 2019113370A RU 2019113370 A RU2019113370 A RU 2019113370A RU 2019113370 A RU2019113370 A RU 2019113370A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- seq
- lymphoma
- combination according
- antibody
- Prior art date
Links
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 title claims 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 title claims 6
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 229960001183 venetoclax Drugs 0.000 claims 5
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (12)
1. Комбинация, содержащая антитело, специфическое в отношении CD19, где указанное антитело содержит область HCDR1, содержащую последовательность SYVMH (SEQ ID NO: 1), область HCDR2, содержащую последовательность NPYNDG (SEQ ID NO: 2), область HCDR3, содержащую последовательность GTYYYGTRVFDY (SEQ ID NO: 3), область LCDR1, содержащую последовательность RSSKSLQNVNGNTYLY (SEQ ID NO: 4), область LCDR2, содержащую последовательность RMSNLNS (SEQ ID NO: 5), и область LCDR3, содержащую последовательность MQHLEYPIT (SEQ ID NO: 6), и венетоклакс, для применения в лечении неходжкинской лимфомы, хронического лимфоцитарного лейкоза и/или острого лимфобластного лейкоза.
2. Комбинация по п. 1, где антитело характеризуется активностью ADCC.
3. Комбинация по п. 1 или 2, где антитело содержит вариабельный домен тяжелой цепи, содержащий последовательность EVQLVESGGGLVKPGG SLKLSCAASGYTFTSY VMHWVRQAPGKGLEWI GYINPYNDGTKYNEKFQ GRVTISSDKSISTAYMEL SSLRSEDTAMYYCARGT YYYGTRVFDYWGQGT LVTVSS (SEQ ID NO: 10), и вариабельный домен легкой цепи с последовательностью DIVMTQSPATLSLSPGER ATLSCRSSKSLQNVNGN TYLYWFQQKPGQSPQL LIYRMSNLNSGVPDRFS GSGSGTEFTLTISSLEPE DFAVYYCMQHLEYPIT FGAGTKLEIK (SEQ ID NO: 11).
4. Комбинация по любому из предыдущих пунктов, где антитело содержит константный домен тяжелой цепи, содержащий последовательность ASTKGPSVFPLAPSSKS TSGGTAALGCLVKDY FPEPVTVSWNSGALTS GVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQT YICNVNHKPSNTKVD KKVEPKSCDKTHTCP PCPAPELLGGPDVFLF PPKPKDTLMISRTPEV TCVVVDVSHEDPEVQ FNWYVDGVEVHNAK TKPREEQFNSTFRVVS VLTVVHQDWLNGKE YKCKVSNKALPAPEE KTISKTKGQPREPQVY TLPPSREEMTKNQVSL TCLVKGFYPSDIAVE WESNGQPENNYKTTP PMLDSDGSFFLYSKL TVDKSRWQQGNVFS CSVMHEALHNHYTQ KSLSLSPGK(SEQ ID NO: 12).
5. Комбинация по любому из предыдущих пунктов, где антитело содержит константный домен легкой цепи, содержащий последовательность RTVAAPSVFIFPPSDE QLKSGTASVVCLLN NFYPREAKVQWKVD NALQSGNSQESVTEQ DSKDSTYSLSSTLTLS KADYEKHKVYACEV THQGLSSPVT KSFNRGEC (SEQ ID NO: 13).
6. Комбинация по любому из предыдущих пунктов, где указанное антитело, специфическое в отношении CD19, и венетоклакс вводятся отдельно.
7. Комбинация по любому из предыдущих пунктов, где венетоклакс вводится до введения антитела, специфического в отношении CD19.
8. Комбинация по любому из предыдущих пунктов, где указанное антитело, специфическое в отношении CD19, и венетоклакс вводятся одновременно.
9. Комбинация по любому из предыдущих пунктов, где указанное антитело, специфическое в отношении CD19, и венетоклакс вводятся в определенный момент времени, при этом оба лекарственных средства проявляют активность у пациента в одно и то же время.
10. Комбинация по любому из предыдущих пунктов для применения в лечении хронического лимфоцитарного лейкоза.
11. Комбинация по любому из предыдущих пунктов для применения в лечении острого лимфобластного лейкоза.
12. Комбинация по любому из предыдущих пунктов для применения в лечении неходжкинской лимфомы, где неходжкинская лимфома выбрана из группы, состоящей из фолликулярной лимфомы, мелкоклеточной лимфоцитарной лимфомы, лимфомы лимфоидной ткани слизистых оболочек, лимфомы маргинальной зоны, диффузной крупноклеточной В-клеточной лимфомы, лимфомы Беркитта и лимфомы из клеток мантийной зоны.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16196184 | 2016-10-28 | ||
EP16196184.2 | 2016-10-28 | ||
PCT/EP2017/077654 WO2018078123A1 (en) | 2016-10-28 | 2017-10-27 | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019113370A true RU2019113370A (ru) | 2020-11-30 |
RU2019113370A3 RU2019113370A3 (ru) | 2021-03-01 |
RU2756405C2 RU2756405C2 (ru) | 2021-09-30 |
Family
ID=57218739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019113370A RU2756405C2 (ru) | 2016-10-28 | 2017-10-27 | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения |
Country Status (24)
Country | Link |
---|---|
US (1) | US20190241656A1 (ru) |
EP (2) | EP3532098B1 (ru) |
JP (2) | JP7094950B2 (ru) |
KR (2) | KR20230028571A (ru) |
CN (2) | CN109890418B (ru) |
AU (1) | AU2017348624A1 (ru) |
BR (1) | BR112019008244A2 (ru) |
CA (1) | CA3037246A1 (ru) |
CY (1) | CY1124648T1 (ru) |
DK (1) | DK3532098T3 (ru) |
ES (1) | ES2871574T3 (ru) |
HR (1) | HRP20210838T1 (ru) |
HU (1) | HUE054496T2 (ru) |
IL (2) | IL266216B2 (ru) |
LT (1) | LT3532098T (ru) |
MX (2) | MX2019004942A (ru) |
PL (1) | PL3532098T3 (ru) |
PT (1) | PT3532098T (ru) |
RS (1) | RS62036B1 (ru) |
RU (1) | RU2756405C2 (ru) |
SG (1) | SG10202104036QA (ru) |
SI (1) | SI3532098T1 (ru) |
WO (1) | WO2018078123A1 (ru) |
ZA (1) | ZA201903302B (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201909715VA (en) | 2017-05-31 | 2019-11-28 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
GB201809746D0 (en) * | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
JP2021535110A (ja) * | 2018-08-31 | 2021-12-16 | アーデーセー セラピューティクス ソシエテ アノニム | 併用療法 |
US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0138854B1 (en) | 1983-03-08 | 1992-11-04 | Chiron Mimotopes Pty. Ltd. | Antigenically active amino acid sequences |
US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
CA2422076A1 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
WO2005012493A2 (en) | 2003-07-31 | 2005-02-10 | Immunomedics, Inc. | Anti-cd19 antibodies |
EA200800094A1 (ru) | 2005-06-20 | 2008-06-30 | Медарекс, Инк. | Антитела cd19 и их использование |
KR101397290B1 (ko) | 2005-12-30 | 2014-05-21 | 메르크 파텐트 게엠베하 | 감소한 면역원성을 가지는 항-cd19 항체 |
SI2059536T1 (sl) | 2006-08-14 | 2014-06-30 | Xencor, Inc. | Optimirana protitelesa, ki ciljajo CD19 |
PT2066349E (pt) | 2006-09-08 | 2012-07-02 | Medimmune Llc | Anticorpos anti-cd19 humanizados e respectiva utilização no tratamento de tumores, transplantação e doenças auto-imunes |
WO2008150494A1 (en) | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
EP2211904B1 (en) | 2007-10-19 | 2016-08-17 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
KR20110122859A (ko) | 2009-02-23 | 2011-11-11 | 그렌마크 파머수티칼스 에스. 아. | Cd19에 결합하는 인간화된 항체 및 그것의 용도 |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20120128586A1 (en) | 2009-06-24 | 2012-05-24 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
EP4083071A3 (en) | 2011-08-16 | 2023-02-22 | MorphoSys AG | Combination therapy with an anti-cd19 antibody and a purine analog |
ES2909722T3 (es) | 2011-08-16 | 2022-05-10 | Morphosys Ag | Terapia de combinación con un anticuerpo anti-CD19 y una mostaza nitrogenada |
ES2818110T3 (es) * | 2014-02-28 | 2021-04-09 | Merck Sharp & Dohme | Tratamiento del cáncer con una combinación que comprende dinaciclib |
SG11201705476WA (en) * | 2015-02-12 | 2017-09-28 | Seattle Genetics Inc | Combination therapy using a cd19-adc and vincristine |
-
2017
- 2017-10-27 AU AU2017348624A patent/AU2017348624A1/en active Pending
- 2017-10-27 HU HUE17797564A patent/HUE054496T2/hu unknown
- 2017-10-27 WO PCT/EP2017/077654 patent/WO2018078123A1/en unknown
- 2017-10-27 CN CN201780067047.1A patent/CN109890418B/zh active Active
- 2017-10-27 PL PL17797564T patent/PL3532098T3/pl unknown
- 2017-10-27 ES ES17797564T patent/ES2871574T3/es active Active
- 2017-10-27 SG SG10202104036QA patent/SG10202104036QA/en unknown
- 2017-10-27 US US16/342,645 patent/US20190241656A1/en active Pending
- 2017-10-27 IL IL266216A patent/IL266216B2/en unknown
- 2017-10-27 RS RS20210792A patent/RS62036B1/sr unknown
- 2017-10-27 IL IL301786A patent/IL301786A/en unknown
- 2017-10-27 DK DK17797564.6T patent/DK3532098T3/da active
- 2017-10-27 EP EP17797564.6A patent/EP3532098B1/en active Active
- 2017-10-27 SI SI201730811T patent/SI3532098T1/sl unknown
- 2017-10-27 BR BR112019008244A patent/BR112019008244A2/pt unknown
- 2017-10-27 CA CA3037246A patent/CA3037246A1/en active Pending
- 2017-10-27 EP EP21165598.0A patent/EP3903821A1/en active Pending
- 2017-10-27 JP JP2019522273A patent/JP7094950B2/ja active Active
- 2017-10-27 KR KR1020237005018A patent/KR20230028571A/ko not_active Application Discontinuation
- 2017-10-27 MX MX2019004942A patent/MX2019004942A/es unknown
- 2017-10-27 PT PT177975646T patent/PT3532098T/pt unknown
- 2017-10-27 RU RU2019113370A patent/RU2756405C2/ru active
- 2017-10-27 CN CN202410183851.8A patent/CN118045175A/zh active Pending
- 2017-10-27 LT LTEP17797564.6T patent/LT3532098T/lt unknown
- 2017-10-27 KR KR1020197012532A patent/KR102500868B1/ko active IP Right Grant
-
2019
- 2019-04-26 MX MX2022016270A patent/MX2022016270A/es unknown
- 2019-05-24 ZA ZA2019/03302A patent/ZA201903302B/en unknown
-
2021
- 2021-05-25 HR HRP20210838TT patent/HRP20210838T1/hr unknown
- 2021-06-10 CY CY20211100512T patent/CY1124648T1/el unknown
-
2022
- 2022-06-22 JP JP2022100006A patent/JP2022137089A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192100T1 (hr) | Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe | |
RU2014103490A (ru) | Комбинированная терапия с помощью антитела к cd19 и аналога пурина | |
RU2019113370A (ru) | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения | |
RU2014103492A (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
JP2017048208A5 (ru) | ||
RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
JP2017507954A5 (ru) | ||
HRP20210945T1 (hr) | Formulacije protutijela anti-cd19 | |
JP2023093495A5 (ru) | ||
JP2022119854A5 (ru) | ||
RU2013113933A (ru) | Антитело к cd38 и леналтдомид или бортезомиб для лечения множественной миеломы и nhl | |
MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
JP2013542194A5 (ru) | ||
JP2017528462A5 (ru) | ||
JP2017507953A5 (ru) | ||
CY1112473T1 (el) | Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα | |
RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
RU2014118741A (ru) | Композиции для лечения ревматоидного артрита и способы их применения | |
PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
NZ592436A (en) | Treatment with anti-alpha2 integrin antibodies | |
NZ590863A (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
RU2018107929A (ru) | Комбинации и их использование | |
JP2019533682A5 (ru) |